Lahann Joerg (Orcid ID: 0000-0002-3334-2053)

EMERGING METHODS IN THERAPEUTICS USING MULTIFUNCTIONAL NANOPARTICLES

First author [Nahal Habibi, Biointerfaces Institute, Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA, nahali@umich.edu]
Second author [Daniel F. Quevedo, Biointerfaces Institute , Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA, danqueve@umich.edu]
Third author [Jason V. Gregory, Biointerfaces Institute, Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA, jvgregor@umich.edu]
Corresponding author [Joerg Lahann, Biointerfaces Institute, Departments of Chemical Engineering, Materials Science and Engineering, Biomedical Engineering and Macromolecular Science and Engineering Program, University of Michigan, Ann Arbor, MI, 48109 USA, Institute of Functional Interfaces (IFG), Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany, lahann@umich.edu]

**Nahal Habibi, Daniel F. Quevedo, Jason V. Gregory contributed equally to this work.

Keywords: Protein Nanoparticles, Nanomedicine, Drug Delivery, Multifunctional Nanoparticles, Clinical Trials, Cellular Hitchhiking, Blood-Brain Barrier, Cancer Therapy

ABSTRACT

Clinical translation of nanoparticle-based drug delivery systems is hindered by an array of challenges including poor circulation time and limited targeting. Novel approaches including designing multifunctional particles, cell-mediated delivery systems and fabrications of protein-based nanoparticles have gained attention to provide new perspectives to current drug delivery obstacles in the interdisciplinary field of nanomedicine. Collectively, these nanoparticle devices are currently being investigated for applications spanning from drug delivery and cancer therapy to medical imaging and immunotherapy. Here, we review the current state of the field, highlight opportunities, identify challenges, and present the future directions of the next generation of multifunctional nanoparticle drug delivery platforms.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/wnan.1625



Graphical Abstract. Novel approaches in designing nanoparticles to overcome challenges faced by traditional nanoparticle-based drug delivery systems.

INTRODUCTION

Research aimed at the development of novel nanoparticle technologies and their prospective use in a variety of medical applications have grown exponentially in recent decades. While broadly defined as colloidal particles ranging in size from nanometers into the submicron range, the scope of their properties, modes of preparation, compositions, and architectures vary vastly. As a result, their potential impact in numerous biomedical applications including drug delivery, tissue engineering, and diagnostics has become increasingly evident. Despite a wide range of tangible efforts, few nanoparticles have had meaningful clinical impact. In fact, during the 20 years following the FDA approval of Doxil in 1995 for the treatment of Kaposi's Sarcoma, fewer than 50 nanomedicines have received FDA approval [1]. Recently published reviews by Anselmo *et al.*[2] and Ventola[3] highlight current clinical trials of nanoparticle formulations while describing challenges impacting their successful translation to the clinic.

Nanoparticle-based drug delivery systems aim to provide several advantages over their free drug counterparts including: (i) protection of loaded cargo from degradation or deactivation, (ii) potential controlled release mechanisms, and (iii) altered pharmacokinetics and specific control of biodistribution [4,5]. Despite their great promise, nanoparticles suffer from rapid clearance from circulation, inefficient delivery to target tissues, and limited ability to cross challenging biological barriers such as the blood-brain barrier [6–8]. Therefore, the development of alternative drug delivery designs have proven essential to address the above-mentioned hurdles.

In response to the challenge to navigate, alter, or interact with complex biological, physiological, or pathological processes, nanoparticle designs and architectures have evolved, in an attempt to address these challenges. However,

while one class of particle or material may address a single barrier, it is unlikely to address them all. For example, in the case of drug delivery for cancer therapy, the bulk and surface properties best suited for this multi-step process – including systemic transport, tumor localization, cellular uptake and effective drug release – are conflicting [9]. Approaches to address this conundrum include the development of multifunctional particles, cell mediated transport mechanisms, and the use of biologically derived materials. Here, we discuss recent advances in the development of such particles, their potential applications with a particular focus on drug delivery and persisting challenges in the field of multifunctional drug delivery carriers.

MULTIFUNCTIONAL NANOPARTICLES

Multifunctional particles can be defined as any particle system with two or more engineered properties. Here, we focus on two distinct types of multifunctional particles – (i) those with surface anisotropy and, (ii) those with bulk anisotropy. In the case of surface anisotropic particles, the bulk composition is often uniform and controlled, post-fabrication surface modifications are used to create non-uniform surface features that diverge from their bulk properties. Conversely, bulk anisotropic particles contain multiple, distinct volumes within a single particle, often comprised of different materials, and as a result have dissimilar bulk properties. Discussed here, a variety of fabrication methods within each class, have been developed.



Figure 1. Techniques for the synthesis of multifunctional nanoparticles. (A) Vapor-assisted deposition of macromolecules to select areas of nanoparticles through Matrix Assisted Pulsed Laser Evaporation (MAPLE). Scale bar, 200 nm. Adapted with permission from [10]. (B) Layer-by-layer fabrication of polymer-coated, hollow silica nanoparticles for temporally controlled release of encapsulated drugs. Scale bar, 100 nm. Adapted with permission from [11] (C) Anisotropic,

multifunctional patchy nanoparticles formed through the use of glancing angle deposition (GLAD). Scale bar, 2 μm. Adapted with permission from [12] (D) Tandem nanoprecipitation and internal phase separation employed to create surface-reactive, patchy nanoparticles prepared through the use of block copolymers (BCPs) and tuning of preparation conditions. Scale bar, 100 nm. Adapted with permission from [13] (E) Surface-reactive, multicompartmental particles fabricated using electrohydrodynamic (EHD) cojetting through the spatially controlled addition of chemically orthogonal surface functional groups. Adapted with permission from [14] (F) Continuous and high-throughput synthesis of multicompartmental nanoparticles through the formation of compound droplets in flow and subsequent UV initiated crosslinking. Scale bar, 100 nm. Adapted with permission from [15].

Surface Anisotropy

Isotropic particles synthesized through a variety of methods can have anisotropic surface properties that are controlled by post-modification techniques. This can be achieved through the utilization of masks or templates, to controllably restrict the regions of particles to be modified [16,17]. Interfaces (liquid-liquid [18], liquid-solid [19], air-liquid [20], and air-solid [21]), where particles are either mechanically placed or spontaneously accumulate, act to mask a portion of each particle while surface modifications are performed within a single phase of a two-phase system (Figure 1A). In other instances, the close packing of particles during the process, as in glancing angle deposition, self-imposes restraints on the surface areas of particles available for modification due to shadowing effects caused by neighboring particles (Figure 1C) [12,22]. Here, it is through the control of the deposition angle that dictates the surface area and pattern achieved. Processes such as physical deposition including etching [23], chemical vapor deposition [10,24], or lithography [25] are used to selectively modify the exposed surfaces producing “patchy” particles. Finally, there are instances where uniform modification of the surface is performed to impart dissimilar particle characteristics from the bulk material (Figure 1B). In all cases, the result is a particle with regions of their surface with varied chemical, electrical, or amphiphilic properties distinct from their bulk properties. Together, these varied properties can be used to selectively modify particle surfaces. Examples with biomedical relevance include the covalent attachment of ligands for systemic targeting [26] or PEGylation to alter particle pharmacokinetics [27].

One of the more popular approaches for biological applications is the attachment of biomolecules to inorganic particles such as gold, or mesoporous silica that would otherwise have no targeting properties and lack biocompatibility. López *et al.* make use of a wax-in-water Pickering emulsion - a solid-liquid interfacial template - to create asymmetrically decorated mesoporous silica particles [28]. Effective delivery to cancer cells is achieved through targeting of cell membrane folate receptors before binding to mitochondria upon cellular uptake, finally delivering the encapsulated drug topotecan. By selectively controlling ligand placement, specific ligand density in each region is optimally maximized. Here, it is with a proper selection of ligands that aims to specifically interact with the cells of interest, namely folic acid, that facilitates increased tumor targeting and subsequent mitochondria binding while releasing the encapsulated payload.

Alternatively, surface modifications can increase cellular interactions and uptake through a more general approach of controlling surface chemistry and thereby affecting surface charge density. Recently, the controlled modification of cationic dendrimers with polyethylene glycol (PEG) has been used for targeting cartilage cells to treat osteoarthritis [29]. Geiger *et al.* make use of the highly controllable size and reactive surface amine groups to optimize surface charge, maximizing cellular uptake while minimizing toxicity, through the subsequent attachment of PEG. After attachment of

the targeting ligand insulin-like growth factor 1 (IGF-1), these particles show increased specific uptake in cartilage cells, minimal toxicity, and significantly reduced disease symptoms.

Bulk Anisotropy

In contrast to the post-modification routes that are used to create multifunctional nanoparticles with surface anisotropy, one or more bulk materials with distinct properties are used to create compositionally anisotropic particles. For example, the synthesis of complex nanoparticles through controlled self-assembly processes can be achieved using block copolymers and variations in the solvent mixture (Figure 1D) [13,30]. On a larger scale, the selective surface functionalization of smaller building block particles can result in the formation of more complex supracolloidal assemblies [31,32]. The production of liposomes [33,34] or disk shaped particles [35,36] made of amphiphilic molecules such as lipids can be formed through similar self-assembly processes. In contrast, flow processes, including microfluidics (Figure 1F) [15,37] and electrohydrodynamic (EHD) co-jetting (Figure 1E) [38–41], utilize the controlled flow of polymer solutions in specific orientations to one another in combination with a method of solidifying the individual particles to form stable colloids. Depending on the orientation of the individual flows, the distinct regions within the resulting particles can be radially anisotropic as is the case with core-shell particles [42,43], or adjacent to one another giving rise to a Janus structure [15,44]. In the latter case, the bulk anisotropy directly translates to a surface anisotropy, which in some cases can be further modified for application specific properties. Alternatively, by taking a layer-by-layer (LBL) approach, nanoparticles can be assembled in a stepwise fashion, again resulting in layered particles with homogeneous surfaces [11,45–47]. In each of the aforementioned processes, particles with chemically distinct regions and properties can be synthesized. Upcoming examples highlight how research groups have leveraged bulk anisotropic particles to create multifunctional particles with potential medical applications.

Nanoparticle research has long been applied for the delivery of therapeutics and biomedical imaging. Particle-based imaging can be achieved via the addition of fluorescent dye molecules, nuclear imaging agents for PET/CT (Positron Emission Tomography – Computed Tomography), SPECT (Single Photon Emission Computed Tomography) [48], and MRI (Magnetic Resonance Imaging) [49,50], or encapsulated inorganic nanoparticles for SERS (Surface-Enhanced Raman Spectroscopy) [51] imaging. The use of multi-compartment particles may allow for these to be incorporated into a single particle system and coupled with controlled release of drugs. Combining the delivery and release of therapeutics while also providing a method of monitoring biodistribution and intracellular fate, termed theranostics, can prove to be a valuable tool within the clinic. Misra *et al.* demonstrated the ability to create biphasic nanoparticles comprising of a PLGA compartment loaded with an imaging agent alongside a second pH-sensing, siRNA-loaded compartment [52]. The synthesized particles demonstrated not only the ability to serve the dual function of particle tracking and therapeutic release but also made use of significant swelling of a single hemisphere to facilitate endosomal escape.

The synthesis of nanoparticles with bulk anisotropy lends itself to the development of multifunctional particles with a unique control over their interactions with other particles or biological systems. For example, the use of dissimilar pH responsive polymers to form distinct regions within a single nanoparticle can be used to individually load and tune the release of encapsulated cargo [53,54]. Gröschel *et al.* made use of block copolymers to create patchy particles capable of guided self-assembly to form supracollodial hierarchical assemblies [55]. In contrast, Varadharajan and co-workers, also working with block copolymers, recently employed tandem nanoprecipitation and internal phase separation techniques to produce nanoparticles with complex structural and chemical anisotropy [13]. The resulting particles and their bulk morphology was dependent upon solution parameters including polymer concentration and solvent ratios.

Variations in these conditions resulted in biphasic anisotropic particles with onion-like, dotted, or lamellar patterns where each surface region could then potentially be selectively modified. Such patterned particles could have future biomedical applications including biosensors through co-enzyme immobilization.

Creating bulk anisotropic Janus particles allows for selective and controlled modifications to be performed on the surface. Rahmani *et al.* demonstrated this through the synthesis and subsequent surface modification of tri-compartmental particles [14]. Here, a similar poly(lactic-co-glycolic acid) (PLGA) base was used in combination with dopants of functional PLA polymers. It was shown that by incorporating small amounts of a functional polymer within the bulk of an otherwise isotropic particle system, controlled surface functionalization through orthogonal click chemistry reactions could be used to selectively decorate the particle surface. This approach allows for the covalent attachment of specific targeting or stealth moieties with control over density, placement, and relative orientation of individual ligands relative to one another. Furthermore, the adaptability of the process suggests that the number of compartments and attached ligands is limited only by the number of orthogonal chemistries that can be performed on the resulting particle.

While the highlighted methods of multifunctional nanoparticles aim towards overcoming biological barriers in the field of drug delivery, a great deal of progress remains to be made. Of particular importance is the ability to translate optimal cell penetrating and drug delivery achieved within *in vitro* systems to clinical relevance. The most daunting of challenges involves maintaining favorable particle attributes for cellular uptake while minimizing *in vivo* clearance from circulation to maximize targeting capabilities. For years, the gold standard of surface modification, PEGylation, promised to be a means to add a stealth-like quality to nano-sized colloids in the bloodstream. However, even to date, the fractions of injected particles remaining in circulation over extended periods of time, while improved, remain disappointing using this method [27]. More concerning is the recent observation of circulating antibodies against PEG as an innate immune response [56,57]. Together, these results motivate current research to identify alternative means to extend particle circulation, reduce their rapid clearance, increase local targeting, and effectively penetrate biological barriers such as the blood-brain barrier (BBB).

CELL-MEDIATED DELIVERY OF NANOPARTICLES

Circulatory cells, as the body's own delivery vehicles, possess inherent abilities specifically long circulation times, natural tissue targeting, and the ability to cross impermeable barriers. These significant properties make them great candidates to address some challenges concerning nanoparticle drug delivery systems [6,58]. One such delivery systems, termed "cellular hitchhiking" is an enhancement of the traditional ones, wherein targeted delivery via body's natural vehicle, i.e., circulatory cells and optimal release of the cargo from engineered nanoparticles are realized in one delivery platform.

Cellular hitchhiking has been performed using a variety of cell types (See Table 1). In this review we focus on red blood cells, leukocytes, and stem cells, all of which have been exploited for the cell-mediated transport of nanoparticles. We furthermore elaborate on various strategies that have been used to incorporate nanoparticles into or conjugate them onto the surface of these circulatory cells.

A. RBCs



Figure 2. Different circulatory cells used in cellular hitchhiking formulations. (A) Scanning electron micrographs of nanogels adsorbed onto the surface of murine RBCs *in vitro*. Scale bar = 1 µm. Adapted with permission from [59] (B) Scanning electron micrographs of hyaluronic acid coated backpack attached to the surface of J774 mouse macrophages after 3 h incubation in cell culture conditions. Scale bar = 5 µm. Adapted with permission from [60] (C) Confocal image of fluorescently labeled nanoparticles conjugated to biotinylated neural stem cell stained with calcein-AM. Scale bar = 10 µm. Adapted with permission from [61] (D) Schematic drawing of circulatory cell-mediated targeting and delivery of nanoparticles.

Red Blood Cells (RBCs)

Constituting > 99% of total blood cells, RBCs are long-circulating cells with a lifespan of 100-120 days in humans and natural carriers of many substances, especially oxygen, in the blood stream [62]. The innate properties of RBCs, such as a long circulation time, reversible deformation, and ability to squeeze through capillaries smaller than their diameter [6,63] make them suitable candidates as platforms for drug delivery systems [62,64].

In general, there exists two main methods to obtain RBC-mediated nanoparticle drug delivery systems: (i) to internally load the NPs into RBCs, or (ii) to attach them onto the surface of the cells. Wu *et al.* fabricated RBC-based micromotors, wherein iron oxide nanoparticles were encapsulated into the RBCs and the motors were powered and activated by ultrasound and an applied magnetic field, respectively [65]. Encapsulation of cargoes into RBCs using hypotonic dilution methods requires the formation of transient pores in the RBC membrane for diffusion of nanoparticles into cells[65] making it more invasive in comparison to anchoring the cargoes on their surface [66,67]. Surface loading can be achieved via non-specific binding (electrostatic, van der Waals, hydrogen bonding and hydrophobic forces) [68], or specific binding (ligand-receptor interactions or chemical conjugation) [66,69].

Adsorption of NPs onto RBCs surfaces has been explored as a means of avoiding rapid clearance by the reticuloendothelial system (RES) [68,70]. As an example, RBC-hitchhiking of model polystyrene NPs led to a 100-fold increase of NPs *in vivo* circulation time [68]. Because surface adsorbed nanoparticles will eventually detach from carrier RBCs due to cell-cell interaction and shear forces, engineering the detachment of nanoparticles and their transfer to microvasculature endothelium will enable targeted organ delivery using RBC hitchhiking [59,71,72]. In a recent study, NPs adsorbed onto RBCs were delivered to the first microcapillary bed that the RBC-NP conjugates encountered downstream to their injection site (Figure2A). Selective placement of intravascular catheters upstream of specific organs delivered RBC-hitchhiked nanoparticles to various target organs such as lung, kidney, and brain. RBC-liposome conjugates injected intravenously showed an increased brain delivery of 11.5% of the injected dose [59] compared to transferrin-targeted nanoparticles having 1% target rates, at best [73]. It is important to optimize the loading ratio of nanoparticles onto the RBCs in order to provide optimal delivery but not induce adverse effects on the carrier cells [74]. To this end, Pan *et al.* designed high-throughput *in vitro* assays to characterize the sensitivity of hitchhiked RBCs to potential damage of adsorbed NPs [75].

Leukocytes

Serving as major components of the adaptive and innate immune system, leukocytes are responsible for fighting inflammation, infection, and tumor growth [76,77]. Leukocytes inherently migrate to areas hard-to-reach by traditional nanoparticles such as inflamed tissue [78], migrate across endothelial barriers [79], and reach the hypoxic area of tumors [80,81], and thus are an attractive cell choice for hitchhiking [64].

Macrophages and monocytes as phagocytic cells can naturally internalize nanoparticles and carry them to target sites that are otherwise largely inaccessible [82–84]. For example, macrophages have been used for delivering various nanocarriers across the blood-brain barrier such as self-assembled polyethyleneimine-poly(ethylene glycol) catalase in a Parkinson's Disease model [85], and gold-silica nanoshells for photothermal therapy for glioma *in vitro* [86] and *in vivo* [87]. In another study, mouse peritoneal macrophages loaded with liposome-doxorubicin were delivered to tumors both in subcutaneous and metastasis xenograft tumor models [88]. The macrophages were viable for up to 12 hours in spite of the time-dependent release of doxorubicin from the liposomes [88]. After internalization, nanoparticles are subject to endosomal degradation [8] that can cause premature drug release, reducing the therapeutic effect [8,60,89] or affecting the migration of the carrier cells [90,91]. To overcome these challenges, nanoparticles that can be immobilized on cell

surfaces while avoiding phagocytosis were proposed (Figure 2B) [60,92,93]. Klyachko *et al.* showed that "backpacks" loaded with a potent antioxidant, catalase, were attached to the surface of macrophages and transmigrated across inflamed BBB in a mouse model of LPS-induced encephalitis [90]. Alongside macrophages, a typical feature of monocytes as circulatory cells to migrate towards inflammation sites along a chemoattractant gradient [94] made them suitable to carry particles to inflamed tissues. Anselmo *et al.* took advantage of IgG-Fc receptor interactions to attach cellular "backpacks" on the surface of monocytes while avoiding phagocytosis due to the polymeric backpacks size, disc like shape, and flexibility. Cellular functions such as transmigration through endothelium, or differentiation into macrophages were unimpaired after attachment of the backpacks onto monocytes. Monocyte-hitchhiked backpacks showed a 9-fold higher accumulation in the inflamed skin compared to non-cell attached backpacks and a 2-fold higher targeting of inflamed lungs than to normal lungs [95].

T cells as key components of adaptive immune system are capable of sensing danger signals from invading pathogens and cancer. Upon antigen presentation, tumor specific T cells become activated to eliminate tumor cells [96]. In the context of adoptive T cell-based strategies, utilizing patient's natural T cells or engineered T cells with chimeric antigen receptors (CAR) to mediate tumor cell eradication has suggested promising new directions [96]. However, one of the major barriers for cell-based therapies is loss of transplanted cell viability and function. Showing the enhancement of cell therapy outcome, Stephan *et al.* reported the immobilization of adjuvant drug-loaded nanoparticles to the surface of therapeutic cells via maleimide-thiol conjugation to provide sustained pseudoautocrine stimulation of the transferred cells *in vivo* [97]. Sustained release of the interleukins (IL-15 and IL-21) from the conjugated nanoparticles mediated robust T cell proliferation *in vivo* and resulted in enhanced eradication of established B16 melanomas [97]. Because of tissue-homing ability of T lymphocytes, they were selected as carriers for lipid nanocapsules loaded with potent topoisomerase I poison SN-38 [98]. The nanocapsules were covalently attached to the surface of polyclonal T lymphocytes to deliver the drug into lymphoma tumors. This approach reduced tumor growth significantly and increased survival compared to free SN-38 and SN-38 loaded lipid nanocapsules alone [98]. Cellular hitchhiking can be taken one step further if the cells play a dual role of transport and therapy. An interesting proof-of-concept study was reported by Wayteck *et al.* which cytotoxic T cells were selected due to both their tumoritropic migratory properties and innate tumor cell killing ability to carry siRNA loaded liposomes [99].

Stem Cells

Stem cell therapy often considered to be vital for tissue engineering and regenerative medicine [100]. A more recent development is the use of specific stem cell lineages such as mesenchymal stem cells (MSCs) and neural stem cells (NSCs) for drug delivery applications [101]. Their tumoritropic migratory nature make them desirable for targeted delivery of therapeutics [102,103] and multimodality imaging agents [104] in cancer therapy.

For designing stem cell-mediated delivery platforms, nanoparticles can be loaded onto the cells surface as a first approach. For example, Doxorubicin loaded nanorattles were surface decorated with anti-CD73 or anti-CD90 to anchor to MSCs through antibody-antigen interaction [105]. These conjugates were able to migrate toward the glioma xenograft and resulted in enhanced tumor cell apoptosis compared to the free drug and the drug-loaded silica nanorattles [105]. In another example, NSCs were chosen as carries due to their ability to overcome high interstitial pressures and penetrate to hypoxic tumor regions. The NSCs mediated the transport of docetaxel-loaded nanoparticles to enhance the efficiency of intratumorally administered nanoparticles. A pH sensitive bond was used to conjugate

nanoparticles to the surface of NSCs *via* biotin-streptavidin interaction (Figure 2C). This hybrid cell-nanoparticle system showed enhanced distribution and retention of the nanoparticles in a tripe negative breast cancer mouse model [61].

In a second approach to formulate stem-cell based delivery platforms, nanoparticles can be encapsulated into the stem cells. Poly-lactic acid nanoparticles and lipid nanocapsules were internalized by marrow-isolated adult multilineage inducible (MIAMI) cells, a subpopulation of MSCs as potential nanoparticle carriers in brain tumor therapy. It was shown that after their direct tumoral injection, loaded MIAMI cells migrated and distributed around the tumor mass [106]. In another example, Gold nanorods (AuNRs) taken up by NSCs demonstrated potential in improvement of photothermal therapy efficiency [107]. When the AuNRs were transported by NSCs after intratumoral injection, broader and more homogenous distribution of AuNR within the tumor was observed compared to free AuNRs. Improved *in vivo* delivery of AuNRs mediated by NSCs resulted in reduced tumor recurrence rates after NIR exposure [107].

Table 1. Advantages, limitations and examples of *in vivo* applications of cellular hitchhiking formulations.

Hitchhiked Cell Type	Cell Type Advantages	Cell Type Limitations	Particle Cargo	Benefits of Cellular Hitchhiking	Ref.
Red blood cells	-Abundant -Long circulation time -Easy isolation	-Limited tissue targeting	-200nm spheres and Rod shape polystyrene particles	-Increased lung targeting	[72,108]
Macrophages /Monocytes	-Ability to phagocytose nanoparticles -Cross biological barriers -Naturally migrate to sites of inflammation -Reach hypoxic areas of tumors	-Low drug loading efficiency -Endosomal degradation of phagocytosed cargo	-Self-assembled polyethyleneimine-poly(ethylene glycol) catalase	-Enhanced delivery of catalase to PD-affected brain regions (crossing blood-brain barrier)	[85,109]
T cells	-Ability to target specific cells -Dual carrier and therapy capability	-Difficult harvesting and handling, -Short *in vivo* lifespan	-300-nm multilamellar lipid nanoparticles loaded with IL-15 and IL-21	-Enhanced tumor elimination in established B16 melanomas	[97,110]
Stem cells	-Ability to internalize nanoparticles -Tumoritropic migratory ability	-Difficult isolation and expansion -Reports of MSCs association with promoting primary and metastatic tumor growth	-Poly(ethylene glycol)-poly(diisopropyl amino) ethyl methacrylate nanoparticles loaded with docetaxel	-Enhanced tumor delivery due to improved migration to hypoxic tumor cores in a triple negative breast cancer (TNBC) mouse model	[61,103]

When designing efficient cell-mediated nanoparticle delivery systems for targeting specific organs, a rational selection of appropriate cells is as important as precisely tuning the properties of nanoparticles. Nonetheless, challenges to this approach include sufficient drug loading capacity, premature drug release, triggered controlled release, preservation of the drug cargo from intracellular degradation, and protection of cell carriers from drug cytotoxic effects. Moreover, cost barriers and sufficient harvesting, or expanding of cells without contamination for reinjection into the body, and efficient migration of cell carriers to the target site are other important concerns. Although there are challenges that needs to be addressed, cell-mediated delivery platforms offer promising opportunities in improving diagnosis and therapeutics for various chronic diseases such as cancer. Developing smart biomaterials, engineering particle design parameters, and utilizing deliberate methods to conjugate nanoparticles to suitable cells can address some of the above-mentioned challenges.

PROTEIN NANOPARTICLES

A recent development in the field of nanoparticle-based drug delivery replaces synthetic polymers with proteins as the primary building blocks of nanoparticles. As a material, proteins show great promise due to their variety, function, design flexibility through genetic engineering, and potential lack of immunogenicity. Three main techniques to develop protein nanoparticles (PNPs) will be explored in this review: *nab* technology, self-assembly and coacervation.



Figure 3. Protein Nanoparticles hold great promise in medicine due to their variety and inherent functionalities. Three main methods exist to synthesize these particles. (A) *Nab* technology works by using a sheer mediated process to force

hydrophobic drugs within proteins and subsequently cause the proteins to aggregate into nanoscale particles. (B) Self-assembly techniques use the expression of specially designed proteins by microorganisms that subsequently self-assemble into structures that can be used for broad variety of therapeutic applications. (C) Coacervation functions by the addition of an organic solvent or reagent to a protein solution, which causes the formation of particles that are subsequently crosslinked using bifunctional crosslinkers.

Nanoparticle Albumin Bound (*nab*) technology

Nab technology is one of the oldest and most developed methods for making PNPs. Developed by Abraxis Bioscience (now a part of Celgene) to create a way of delivering paclitaxel, *nab*-technology forces highly hydrophobic drugs into the internal hydrophobic pockets of human serum albumin (HSA) using a high-pressure manufacturing process (Figure 3A). Paclitaxel is normally administered using harsh organic solvents [111]. By packaging the drug in albumin, a common protein in human blood that is not only water soluble but also has a naturally long circulation time, the drug can be delivered with reduced side effects [112]. The first FDA approved *nab* product was Abraxane, which has been approved for use as a first line therapy for non-small cell lung cancer, metastatic adenocarcinoma, and as treatment for metastatic breast cancer. Additionally, Abraxane is in Japanese clinical trials by Celgene for use in metastatic pancreatic cancer and gastric metastatic cancer.

In addition to the success of Abraxane, multiple other *nab* technologies are under investigation at both the industrial and academic level. ABI-008 through ABI-011 are a family of *nab* based drugs that are undergoing clinical trials. For example, AB-009 (*nab*-rapamycin/sirolimus, brand name Tarzifix™) is under investigation by Aadi Bioscience (licensed from Celgene) in a variety of phase 1 and 2 trials ranging from Metastatic Colorectal Cancer to Pulmonary Arterial Hypertension (see Table 2). In addition to multiple clinical trials, next generation *nab* technologies are actively being investigated. For example, actively targeted variants of *nab* particles have been made. Thao *et al.* developed *nab* particles made out of lactosylated albumin loaded with a mixture of paclitaxel and doxorubicin. The particles were designed to take advantage of the high affinity of lactose to asialoglycoprotein receptors, which are overexpressed in hepatocellular carcinomas. The particles were shown through *in vitro* and *in vivo* experiments to have increased accumulation in liver vs control (Pac/dox loaded into naïve albumin *nab* particles) [113]. In addition to applying targeting moieties to *nab* particles, there has been work done on the use of adjuvants in potential therapies. An interesting case was the work performed by Kinoshita *et a.l*, where Abraxane was delivered with a S-nitrosated HSA dimers [114]. By modifying the HSA dimer through a disulfide bond on the free cysteine on albumin, they were able to release nitrous oxide (NO) as a vasodialator. This effect increased the delivery and efficacy of Abraxane in colon cancer and melanoma murine models, and reduced metastases. Creative combinations of therapies such as this show potential translatability in that they follow the pharmaceutical industry model of expanding the potential of a therapy through combination studies.

While showing great potential, *nab* technologies have potential downsides. Early work has shown that Abraxane is associated with more rapid plasma clearance compared to the traditional liposomal formulation of paclitaxel (Taxol) [115]. Abraxane nanoparticles are stable in *ex vivo* saline solutions, but the particles quickly break down into albumin-paclitaxel complexes following administration [112]. This poor colloidal stability has been suggested as the reason behind the rapid clearance of the nanoparticles [116]. Work has been done to improve the colloidal stability of *nab* particles [116,117], but these works have used albumin bound paclitaxel particles made through coacervation techniques, not high pressure homogenization as Abraxane and other *nab* particles are. Further studies are thus needed to substantiate claims of improved stability. This problem of using coacervation synthesized particles as a stand-in for Abraxane has also been seen in other studies with potentially impactful advances [118, 119]. In addition to poor clearance profiles, *nab* technology has the inherent downside of harsh synthetic conditions [120]. This potentially limits

the use of *nab* technology to deliver active proteins, such as enzymes, in ways that other synthetic routes that are able to [121]. Excellent reviews of *nab* technologies have been written by Hawkins *et al.* and Tan *et al.*, among others, which we recommend for further reading [122,123]. *Nab* technology has shown the clinical potential of proteins as nanocarriers in medicine.

Table 2. Past, current or planned clinical trials of Abraxane-like *Nab* Nanoparticles.

Drug code	Active Ingredient	Mechanism of Action	Clinical Trial Phase	Trial Description and Indication	Trial Outcome	Trial Years	Sponsor(s)	Clinical Trial Number
ABI-008	Docetaxel	Chemotherapeutic, a semi-synthetic taxane analogue of paclitaxel	1/2	Single Agent Therapy of *nab*-Docetaxel for Hormone Refractory Prostate Cancer	Completed	2007-2011	Celgene Corporation	NCT00477529
			1/2	Single Agent Therapy of *nab*-Docetaxel for Metastatic Breast Cancer	Terminated, reason not given	2007-2008	Celgene Corporation	NCT00531271
ABI-009	Rapamycin (aka Sirolimus)	mTOR inhibitor, FDA approved as small molecule drug for the prevention of organ transplant rejection and the treatment of lymphangioleiomy-omatosis	1	Single Agent Therapy of *nab*-Rapamycin for Advanced Non-hematologic Malignancies	Completed	2007-2011	Celgene Corporation	NCT00635284
			1/2	Single Agent Therapy of *nab*-Rapamycin for Non-muscle Invasive Bladder Cancer	Ongoing	2014-2020 (Planned)	Aadi, LLC and National Cancer Institute	NCT02009332
			2	Single Agent Therapy of *nab*-Rapamycin for Advanced Perivascular Epithelioid Cell Tumors (PEComa), Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation	Ongoing	2015-2020 (Planned)	Aadi, LLC	NCT02494570, NCT03817515
			1	Single Agent Therapy of *nab*-Rapamycin for Severe Pulmonary Arterial Hypertension	Ongoing	2017-2020 (Planned)	Aadi, LLC	NCT02587325

1	Single Agent Therapy of *nab*-Rapamycin for Advanced Cancer With mTOR Mutations	Ongoing	2016-2019 (Planned)	Mayo Clinic and National Cancer Institute	NCT02646319
1	Combination Therapy of *nab*-Rapamycin, Temozolomide, and Irinotecan Hydrochloride for Pediatric Patients With Recurrent or Refractory Solid Tumors	Ongoing	2017-2020 (Planned)	Children's Oncology Group and National Cancer Institute	NCT02975882
1/2	Combination Therapy of Nivolumab and *Nab*-rapamycin for Advanced Sarcoma	Ongoing	2017-2020 (Planned)	Sarcoma Oncology Research Center, LLC and Aadi, LLC	NCT03190174
1/2	Combination Therapy of *Nab*-rapamycin, FOLFOX and Bevacizumab as First-line Therapy for Advanced or Metastatic Colorectal Cancer	Ongoing	2018-2021 (Planned)	Aadi, LLC	NCT03439462
2	Single Agent Therapy of *nab*-Rapamycin for Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma	Ongoing	2018-2021 (Planned)	Aadi, LLC	NCT03463265
1	Single Agent Therapy of *nab*-Rapamycin for Surgically-Refractory Epilepsy	Ongoing	2018-2019 (Planned)	Seattle Children's Hospital and Aadi, LLC	NCT03646240
1	Combination Therapy of *Nab*-rapamycin, Pomalidomide and Dexamethasone for Relapsed	Planned	2018-2024 (Planned)	Massachusetts General Hospital and	NCT03657420

				and Refractory Multiple Myeloma			Aadi, LLC	
			1/2	Combination Therapy of *nab*-Rapamycin and Pazopanib Hydrochloride for Nonadipocytic Soft Tissue Sarcomas	Ongoing	2019-2021 (Planned)	University of Washington	NCT03660930
			2	Single Agent Therapy of *nab*-Rapamycin for Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System	Ongoing	2018-2020 (Planned)	Aadi, LLC and Ochsner Health System	NCT03670030
			2	Single Agent Therapy of *nab*-Rapamycin for Genetically-confirmed Leigh or Leigh-like Syndrome	Planned	2019-2023 (Planned)	Aadi, LLC	NCT03747328
ABI-010	Tanespimycin	Aka 17AAG a Hsp90 inhibitor analogue of geldanamycin currently under investigation for various indications	1	Combination Therapy *nab*-Paclitaxel and *nab*-17AAG for Advanced Non-Hematologic Malignancies	Withdrawn before enrolling its first participant	2012-2014	Celgene	NCT00820768
ABI-011	IDN 5404	Thiocolchicine an alogue. A dimer shown to have vascular	1	Single Agent Therapy of *nab*-IDN 5404 for Advanced Solid Tumors or Lymphomas	Terminated, reason not given	2011-2014	Celgene Corporation	NCT01163071
			1	Single Agent Therapy of *nab*-	Ongoing	2017-	NantBioScience	NCT0258282

disrupting activity and to be a topoisomerase I inhibitor	IDN 5404 for Advanced Solid Tumors or Lymphomas	2019 (Planned)	, Inc.	7

Self-assembled protein nanoparticles

Self-assembled nanoparticles are nanoscale structures made of protein complexes that can self-assemble to form PNPs (Figure 3B). These structures are designed by creating recombinant proteins that contain oligomerization-domains that create structure, and then a variety of other domains that can result in specific activity [124]. The synthetic methods and design strategies for nanoscale protein structures have been excellently summarized in recent reviews [124,125].

An interesting application of self-assembled PNPs in the medical space is the use of caged protein nanoparticles [126]. These particles are made up of protein units that self-assemble under specific conditions into hollow cage-like structures. Inside these structures it is then possible to load a variety of therapeutic molecules such as enzymes[127] and small molecules [128]. In a recent study, Kawakami *et al.* designed a 60-mer protein cage with a defined structure. Notably, they were able to design the particle so that specific residues faced either the exterior or interior of the cage, and subsequently were able to covalently modify these particles [129]. These covalent modifications were done using disulfide bonds, and thus this system could be designed to carry a drug in the inside of the cage, and then be released in a reducing environment.

These self-assembled nanoparticle technologies are elegant, sophisticated, and complicated, but these very characteristics call to question their potential for translation into the clinic in the near future. Most of the proteins used in these nanoparticles are not only novel recombinant proteins, but are also expressed in non-mammalian organisms such as *Escherichia coli* [129]. Expression in non-human organisms of recombinant proteins presents many regulatory problems and costs, as has been shown though the past 30 years with the rise of recombinant antibody and antibody fragment (Fab) technology [130]. Yet, with careful development, the rise of the multi-billion dollar biological therapeutics field shows the potential for progressively more sophisticated therapies to enter the market.

Coacervation-synthesized protein nanoparticles

During coacervation, a "coacervation agent", usually an organic solvent such as acetone or ethanol, is added to a concentrated aqueous solution of a protein of interest. The coacervating agent dehydrates the proteins and causes the precipitation of nanoparticles from the solution. The particles can then be crosslinked, rendering them water insoluble (Figure 3C). By controlling a variety of conditions, including the protein type, the rate of addition of the coacervating agent, the temperature of the procedure, the salt content of the solution, and the crosslinking agent and time, the resulting nanoparticle size, mechanical properties, and functionalities can be tailored to fit the needs of the application [131,132]. In addition, the process is highly reproducible, and the particles can be surface functionalized and loaded with a variety of therapeutics [133–135].

Initial work using coacervation focused on albumin proteins, but the field is now expanding to a variety of different proteins and applications. A wide variety of different proteins have been formulated into nanoparticles, as detailed in a recent review [136]. These proteins have been used in applications such as the packaging of small molecules and micro-nutrients for the food industry. Guo *et al.* produced whey protein nanoparticles loaded with zinc and showed that particle size could be controlled by modulating the amount of zinc added and the synthesis conditions. Additionally, they showed through *in vitro* experiments that site specific delivery of zinc was possible by pH dependent release of the micronutrient from the PNPs to its nutritionally relevant site, the intestinal track, as opposed to the stomach [137].

Through coacervation techniques, PNPs have been prepared from a wide variety of polypeptides and proteins for therapeutic purposes [121,138,139]. A recent publication that used the PNP technologies developed by the Champion lab demonstrated a proof of concept of a universal influenza virus [140]. Nanoparticles were comprised of a core of a tetramer of M2e epitopes from four influenza subtypes, and surface modified with one of two different recombinant mutants of the highly conserved hemagglutinin (HA) stalks from various subclasses of influenza. By creating a cocktail of

two nanoparticles, each modified with different recombinant HA variants, Deng *et al.* elicited universal protection to a wide variety of influenza subtypes. While the use of the highly conserved M2e epitopes has been attempted before in vaccines, these vaccines were constructed from virus-like particles (VLP) loaded with epitopes and resulted in off target immune responses due to the carrier proteins in the VLP [141,142]. PNPs made almost entirely of proteins of interest, as was demonstrated in the work by Deng *et al.*, can avoid off target effect problems. Additionally, coacervation-manufactured PNPs, as opposed to the self-assembled or VLP counterparts, have greater stability over a large range of physiological environments, and studies have shown that they can potentially create cold chain-independent therapies [143]. A clear downside of coacervation particles is inherent in the simplicity of their synthetic method, in that it creates homogeneous distributions of proteins throughout each particle. Only radial complexity through surface modifications methods are able to provide any kind of anisotropy to the particles, as opposed to technologies such as those discussed in previous sections.

Another research avenue leveraging biologically-derived materials focuses on engineering extracellular vesicle-based systems such as exosomes. Their natural stability in the blood stream, presence of multiple adhesive proteins on their surface, and ability to transport functional biomolecules such as proteins and RNAs between cells, position them as potential drug carriers [144–146]. Exosomes have been exploited for targeted delivery of a wide range of therapeutic cargos such as siRNA to cross the BBB [147], the chemotherapeutic drug doxorubicin to solid tumors[148] and the antioxidant agent curcumin to inflammatory cells[149]. There are, however, limitations such as difficulties in scalability, and reproducibility, along with low drug loading capacity of well-characterized extracellular vesicles that have restricted their clinical and pharmaceutical adoption [150]. In contrast with exosomes, particles that use proteins as their primary building blocks avoid most of these hurdles, and show similar positive characteristics. In addition, proteins have highly established manufacturing processes that have resulted in a plethora of products in the market, and thus have a more direct path to the clinic.

Knowledge of protein folding and biochemistry has advanced to the point where novel structures and functions can be built *de novo* through either first principles engineering, as demonstrated in a variety of self-assembled nanoparticles previously described, or through directed evolution, as has been seminally shown by the work of Frances Arnold and colleagues [151]. However, the use of novel proteins does raise questions of translatability of technologies that are based on almost entirely recombinant proteins and have no analogues in the clinic or even the human body. Additionally, new proteins offer the ability to potentially use the function-follows-form principles of proteins to build complex, compartmentalized nanomachines from protein nanoparticles, though this possibility has yet to be fully explored. The large number of different synthetic routes, functionalities and applications of nanoparticles based on proteins as their building blocks that have been recently developed and commercialized shows the bright potential for PNPs as a revolutionary form of nanoparticles in medicine.

CONCLUSION

The field of nanoparticle-based drug delivery systems is currently at the verge of entering the clinical arena. A wide range of clinical trials that involve nanomedicines are currently being pursued. In spite of the increased acceptance and major technological progress in recent decades, the field of nanoparticle engineering is still severely limited by inefficient targeting and the lacking ability to cross challenging biological barriers, such as the blood-brain barrier. This fuels a continuous quest for novel and improved nanoparticle systems that can be accessed by scalable and flexible manufacturing processes. Building on previous work with electrohydrodynamic cojetting, novel polymer/protein hybrid nanoparticles comprised of multiple internal compartments may become particularly attractive candidates for

nanomedicine-based combination therapies (Figure 4A). In this case, polymer chemistry is merged with protein biochemistry to design nanoparticles where proteins *de facto* become one of the repletion units in engineered nanocarriers. Such an approach combines the versatility and targeting capabilities of synthetic nanoparticles with the excellent circulation and biodistribution as well as rapid clearance in RES organs typically observed for proteins. As an example, scanning electron microscopy image of bicompartmental nanoparticles made by electrohydrodynamic co-jetting is shown in Figure 4B. Here, one compartment is made from a PEG/insulin "co-polymer" system, whereas the second compartment is comprised of PEG/hemoglobin. Each compartment stained with a distinct fluorescent marker, and subsequently resolved using Structured Illumination Microscopy is shown as an inset in Figure 4B. These and other advances will be necessary to design, engineer and manufacture the next generation of nanoparticle drug delivery platforms.



Figure 4. Multicompartmental protein nanoparticles can be made through electrohydrodynamic co-jetting, as shown in (A). As an example, we synthesized particles with two compartments, one made of Insulin and the other of Hemoglobin. The particles are spherical as shown in the electron micrograph in (B), and show a clear bicompartmental nature when each compartment is selectively loaded with a fluorescent dye and imaged using structured illumination microscopy (insert). Scale bar is 200nm.

ACKNOWLEDGEMENT

The authors would like to acknowledge funding from the Defense Threat Reduction Agency (HDTRA-1-15-1-0045). DFQ acknowledges support from the National Science Foundation Graduate Research Fellowship under Grant No. (1256260 DGE).

FIGURES AND TABLES

Table 1. Advantages, limitations and examples of in vivo applications of cellular hitchhiking formulations.

Hitchhiked Cell Type	Cell Type Advantages	Cell Type Limitations	Particle Cargo	Benefits of Cellular Hitchhiking	Ref.
Red blood cells	-Abundant -Long circulation time -Easy isolation	-Limited tissue targeting	-200nm spheres and Rod shape polystyrene particles	-Increased lung targeting	[72,108]
Macrophages /Monocytes	-Ability to phagocytose nanoparticles -Cross biological barriers -Naturally migrate to sites of inflammation -Reach hypoxic areas of tumors	-Low drug loading efficiency -Endosomal degradation of phagocytosed cargo	-Self-assembled polyethyleneimine-poly(ethylene glycol) catalase	-Enhanced delivery of catalase to PD-affected brain regions (crossing blood-brain barrier)	[85,109]
T cells	-Ability to target specific cells -Dual carrier and therapy capability	-Difficult harvesting and handling, -Short in vivo lifespan	-300-nm multilamellar lipid nanoparticles loaded with IL-15 and IL-21	-Enhanced tumor elimination in established B16 melanomas	[97,110]
Stem cells	-Ability to internalize nanoparticles -Tumoritropic migratory ability	-Difficult isolation and expansion -Reports of MSCs association with promoting primary and metastatic tumor growth	-Poly(ethylene glycol)-poly(diisopropyl amino) ethyl methacrylate nanoparticles loaded with docetaxel	-Enhanced tumor delivery due to improved migration to hypoxic tumor cores in a triple negative breast cancer (TNBC) mouse model	[61,103]

Table 2. Past, current or planned clinical trials of Abraxane-like *Nab* Nanoparticles.

Drug code	Active Ingredient	Mechanism of Action	Clinical Trial Phase	Trial Description and Indication	Trial Outcome	Trial Years	Sponsor(s)	Clinical Trial Number
ABI-008	Docetaxel	Chemotherapeutic, a semi-synthetic taxane analogue of paclitaxel	1/2	Single Agent Therapy of *nab*-Docetaxel for Hormone Refractory Prostate Cancer	Completed	2007-2011	Celgene Corporation	NCT00477529
			1/2	Single Agent Therapy of *nab*-Docetaxel for Metastatic Breast Cancer	Terminated, reason not given	2007-2008	Celgene Corporation	NCT00531271
ABI-009	Rapamycin (aka Sirolimus)	mTOR inhibitor, FDA approved as small molecule drug for the prevention of organ transplant rejection and the treatment of lymphangioleiomy-omatosis	1	Single Agent Therapy of *nab*-Rapamycin for Advanced Non-hematologic Malignancies	Completed	2007-2011	Celgene Corporation	NCT00635284
			1/2	Single Agent Therapy of *nab*-Rapamycin for Non-muscle Invasive Bladder Cancer	Ongoing	2014-2020 (Planned)	Aadi, LLC and National Cancer Institute	NCT02009332
			2	Single Agent Therapy of *nab*-Rapamycin for Advanced Perivascular Epithelioid Cell Tumors (PEComa), Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation	Ongoing	2015-2020 (Planned)	Aadi, LLC	NCT02494570, NCT03817515
			1	Single Agent Therapy of *nab*-Rapamycin for Severe Pulmonary Arterial Hypertension	Ongoing	2017-2020 (Planned)	Aadi, LLC	NCT02587325

1	Single Agent Therapy of *nab*-Rapamycin for Advanced Cancer With mTOR Mutations	Ongoing	2016-2019 (Planned)	Mayo Clinic and National Cancer Institute	NCT02646319
1	Combination Therapy of *nab*-Rapamycin, Temozolomide, and Irinotecan Hydrochloride for Pediatric Patients With Recurrent or Refractory Solid Tumors	Ongoing	2017-2020 (Planned)	Children's Oncology Group and National Cancer Institute	NCT02975882
1/2	Combination Therapy of Nivolumab and *Nab*-rapamycin for Advanced Sarcoma	Ongoing	2017-2020 (Planned)	Sarcoma Oncology Research Center, LLC and Aadi, LLC	NCT03190174
1/2	Combination Therapy of *Nab*-rapamycin, FOLFOX and Bevacizumab as First-line Therapy for Advanced or Metastatic Colorectal Cancer	Ongoing	2018-2021 (Planned)	Aadi, LLC	NCT03439462
2	Single Agent Therapy of *nab*-Rapamycin for Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma	Ongoing	2018-2021 (Planned)	Aadi, LLC	NCT03463265
1	Single Agent Therapy of *nab*-Rapamycin for Surgically-Refractory Epilepsy	Ongoing	2018-2019 (Planned)	Seattle Children's Hospital and Aadi, LLC	NCT03646240
1	Combination Therapy of *Nab*-rapamycin, Pomalidomide and Dexamethasone for Relapsed	Planned	2018-2024 (Planned)	Massachusetts General Hospital and	NCT03657420

				and Refractory Multiple Myeloma			Aadi, LLC	
			1/2	Combination Therapy of *nab*-Rapamycin and Pazopanib Hydrochloride for Nonadipocytic Soft Tissue Sarcomas	Ongoing	2019-2021 (Planned)	University of Washington	NCT03660930
			2	Single Agent Therapy of *nab*-Rapamycin for Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System	Ongoing	2018-2020 (Planned)	Aadi, LLC and Ochsner Health System	NCT03670030
			2	Single Agent Therapy of *nab*-Rapamycin for Genetically-confirmed Leigh or Leigh-like Syndrome	Planned	2019-2023 (Planned)	Aadi, LLC	NCT03747328
ABI-010	Tanespimycin	Aka 17AAG a Hsp90 inhibitor analogue of geldanamycin currently under investigation for various indications	1	Combination Therapy *nab*-Paclitaxel and *nab*-17AAG for Advanced Non-Hematologic Malignancies	Withdrawn before enrolling its first participant	2012-2014	Celgene	NCT00820768
ABI-011	IDN 5404	Thiocolchicine an alogue. A dimer shown to have vascular	1	Single Agent Therapy of *nab*-IDN 5404 for Advanced Solid Tumors or Lymphomas	Terminated, reason not given	2011-2014	Celgene Corporation	NCT01163071
			1	Single Agent Therapy of *nab*-	Ongoing	2017-	NantBioScience	NCT0258282

disrupting activity and to be a topoisomerase I inhibitor	IDN 5404 for Advanced Solid Tumors or Lymphomas	2019 (Planned)	, Inc.	7



Graphical Abstract. Novel approaches in designing nanoparticles to overcome challenges faced by traditional nanoparticle-based drug delivery systems.



Figure 1. Techniques for the synthesis of multifunctional nanoparticles. (A) Vapor-assisted deposition of macromolecules to select areas of nanoparticles through Matrix Assisted Pulsed Laser Evaporation

(MAPLE). Scale bar, 200 nm. Adapted with permission from [10]. (B) Layer-by-layer fabrication of polymer-coated, hollow silica nanoparticles for temporally controlled release of encapsulated drugs. Scale bar, 100 nm. Adapted with permission from [11] (C) Anisotropic, multifunctional patchy nanoparticles formed through the use of glancing angle deposition (GLAD). Scale bar, 2 μm. Adapted with permission from [12] (D) Tandem nanoprecipitation and internal phase separation employed to create surface-reactive, patchy nanoparticles prepared through the use of block copolymers (BCPs) and tuning of preparation conditions. Scale bar, 100 nm. Adapted with permission from [13] (E) Surface-reactive, multicompartmental particles fabricated using electrohydrodynamic (EHD) cojetting through the spatially controlled addition of chemically orthogonal surface functional groups. Adapted with permission from [14] (F) Continuous and high-throughput synthesis of multicompartmental nanoparticles through the formation of compound droplets in flow and subsequent UV initiated crosslinking. Scale bar, 100 nm. Adapted with permission from [15].

A. RBCs



Figure 2. Different circulatory cells used in cellular hitchhiking formulations. (A) Scanning electron micrographs of nanogels adsorbed onto the surface of murine RBCs *in vitro*. Scale bar = 1 µm. Adapted with permission from [59] (B) Scanning electron micrographs of hyaluronic acid coated backpack attached to the surface of J774 mouse macrophages after 3 h incubation in cell culture conditions. Scale bar = 5 µm. Adapted with permission from [60] (C) Confocal image of fluorescently labeled nanoparticles conjugated to biotinylated neural stem cell stained with calcein-AM. Scale bar = 10 µm.

Adapted with permission from [61] (D) Schematic drawing of circulatory cell-mediated targeting and delivery of nanoparticles.



Figure 3. Protein Nanoparticles hold great promise in medicine due to their variety and inherent functionalities. Three main methods exist to synthesize these particles. (A) *Nab* technology works by using a sheer mediated process to force hydrophobic drugs within proteins and subsequently cause the proteins to aggregate into nanoscale particles. (B) Self-assembly techniques use the expression of specially designed proteins by microorganisms that subsequently self-assemble into structures that can be used for broad variety of therapeutic applications. (C) Coacervation functions by the addition of an organic solvent or reagent to a protein solution, which causes the formation of particles that are subsequently crosslinked using bifunctional crosslinkers.



Figure 4. Multicompartmental protein nanoparticles, whose synthesis and characterization will be described in upcoming publications by our group, can be made through electrohydrodynamic co-jetting, as shown in (A). As an example, we synthesized particles with two compartments, one made of Insulin and the other of Hemoglobin. The particles are spherical as shown in the electron micrograph in (B), and show a clear bicompartmental nature when each compartment is selectively loaded with a fluorescent dye and imaged using structured illumination microscopy (insert). Scale bar is 200nm.

REFERENCES

[1] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based Medicines : A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res 2016;33:2373–87. doi:10.1007/s11095-016-1958-5.

[2] Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med 2016;1:10–29. doi:10.1002/btm2.10003.

[3] Ventola CL. Progress in Nanomedicine : Approved and Investigational Nanodrugs. P & T 2017;42:742–55.

[4] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotec 2007;2:751–60. doi:10.1038/nnano.2007.387

[5] Cheng Z, Zaki A Al, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional Nanoparticles : Cost Versus Benefits of Adding Targeting and Imaging Capabilities. Science 2012;338: 903-10. doi:10.1126/science.1226338

[6] Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: Taking advantage of circulatory cells to target nanoparticles. J Control Release 2014;190:531-41. doi:10.1016/j.jconrel.2014.03.050.

[7] Agrahari V, Agrahari V, Mitra AK. Next generation drug delivery : circulatory cells- mediated nanotherapeutic approaches. Expert Opin Drug Deliv 2017;14:285–9. doi:10.1080/17425247.2017.1254614.

[8] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015;33:941-51. doi:10.1038/nbt.3330.

[9] Zou H, Wang Z, Feng M. Nanocarriers with tunable surface properties to unblock bottlenecks in systemic drug and gene delivery. J Control Release 2015;214:121–33. doi:10.1016/J.JCONREL.2015.07.014.

[10] Shepard KB, Christie DA, Sosa CL, Arnold CB, Priestley RD. Patchy Janus particles with tunable roughness and composition via vapor-assisted deposition of macromolecules. Appl Phys Lett 2015;106:093104. doi:10.1063/1.4913913.

[11] Palanikumar L, Jeena MT, Kim K, Oh JY, Kim C, Park MH, Ryu JH. Spatiotemporally and Sequentially- Controlled Drug Release from Polymer Gatekeeper – Hollow Silica Nanoparticles. Sci Rep 2017;7:1–11. doi:10.1038/srep46540.

[12] Pawar AB, Kretzschmar I. Multifunctional Patchy Particles by Glancing Angle Deposition. Langmuir 2009;25:9057–63. doi:10.1021/la900809b.

[13] Varadharajan D, Turgut H, Lahann J, Yabu H, Delaittre G. Surface-Reactive Patchy Nanoparticles

and Nanodiscs Prepared by Tandem Nanoprecipitation and Internal Phase Separation. Adv Funct Mater 2018;1800846:1–11. doi:10.1002/adfm.201800846.

[14] Rahmani S, Saha S, Durmaz H, Donini A, Misra AC, Yoon J, Lahann J. Chemically orthogonal three-patch microparticles. Angew Chemie - Int Ed 2014;53:2332–8. doi:10.1002/anie.201310727.

[15] Nie Z, Li W, Seo M, Xu S, Kumacheva E. Janus and ternary particles generated by microfluidic synthesis: Design, synthesis, and self-assembly. J Am Chem Soc 2006;128:9408–12. doi:10.1021/ja060882n.

[16] Hong L, Jiang S, Granick S. Simple Method to Produce Janus Colloidal Particles in Large Quantity. Langmuir 2006;22:9495–9. doi:10.1021/la062716z.

[17] Paunov BVN, Cayre OJ. Supraparticles and "Janus" Particles Fabricated by Replication of Particle Monolayers at Liquid Surfaces Using a Gel Trapping Technique. Adv Mater 2004;16:788–91. doi:10.1002/adma.200306476.

[18] Zhang J, Jin J, Zhao H. Surface-initiated free radical polymerization at the liquid-liquid interface: A one-step approach for the synthesis of amphiphilic janus silica particles. Langmuir 2009;25:6431–7. doi:10.1021/la9000279.

[19] Takahara YK, Ikeda S, Ishino S, Tachi K, Ikeue K, Sakata T, Hasegawa T, Mori H, Matsumura M, Ohtani B. Asymmetrically modified silica particles: A simple particulate surfactant for stabilization of oil droplets in water. J Am Chem Soc 2005;127:6271–5. doi:10.1021/ja043581r.

[20] Petit L, Manaud JP, Mingotaud C, Ravaine S, Duguet E. Sub-micrometer silica spheres dissymmetrically decorated with gold nanoclusters. Mater Lett 2001;51:478–84. doi:10.1016/S0167-577X(01)00338-X.

[21] Jang SG, Choi DG, Heo CJ, Lee SY, Yang SM. Nanoscopic ordered voids and metal caps by controlled trapping of colloidal particles at polymeric film surfaces. Adv Mater 2008;20:4862–7. doi:10.1002/adma.200702851.

[22] Zhao YP, Ye DX, Wang GC, Lu TM. Novel Nano-Column and Nano-Flower Arrays by Glancing Angle Deposition. Nano Lett 2002;2:351–4. doi:10.1021/nl0157041.

[23] Nikravan G, Haddadi-Asl V, Salami-kalajahi M. Synthesis of dual temperature – and pH-responsive yolk-shell nanoparticles by conventional etching and new deswelling approaches: DOX release behavior. Colloids Surfaces B Biointerfaces 2018;165:1–8. doi:10.1016/j.colsurfb.2018.02.010.

[24] Liang BY, Jordahl JH, Ding H, Deng X, Lahann J. Uniform Coating of Microparticles using CVD Polymerization. Chemical Vapor Deposition 2015;288–93. doi:10.1002/cvde.201507197.

[25] Yake AM, Snyder CE, Velegol D. Site-specific functionalization on individual colloids: Size control, stability, and multilayers. Langmuir 2007;23:9069–75. doi:10.1021/la7011292.

[26] Yake AM, Zahr AS, Jerri HA, Pishko M V., Velegol D. Localized functionalization of individual

colloidal carriers for cell targeting and imaging. Biomacromolecules 2007;8:1958–65. doi:10.1021/bm070071r.

[27] Rahmani S, Villa CH, Dishman AF, Grabowski ME, Pan DC, Durmaz H, Misra AC, Colón-Meléndez L, Solomon MJ, Muzykantov VR, Lahann J. Long-circulating Janus nanoparticles made by electrohydrodynamic co-jetting for systemic drug delivery applications. J Drug Target 2015;23:750–8. doi:10.3109/1061186X.2015.1076428.

[28] Lopez V, Rocio Villegas M, Rodriguez V, Villaverde G, Lozano D, Baeza A, Vallet-Regí M. Janus Mesoporous Silica Nanoparticles for Dual Targeting of Tumor Cells and Mitochondria. Appl Mater Interfaces 2017;9:26697–706. doi:10.1021/acsami.7b06906.

[29] Geiger BC, Wang S, Padera RF, Grodzinsky AJ, Hammond PT. Cartilage-penetrating nanocarriers improve delivery and efficacy of growth factor treatment of osteoarthritis. Sci Transl Med 2018;10:1-12. doi: 10.1126/scitranslmed.aat8800.

[30] Shimoda A, Sawada S, Kano A, Maruyama A, Winnik M, Akiyoshi K. Dual crosslinked hydrogel nanoparticles by nanogel bottom-up method for sustained-release delivery. Colloids Surfaces B Biointerfaces 2012;99:38–44. doi:10.1016/j.colsurfb.2011.09.025.

[31] Song J, Wu B, Zhou Z, Zhu G, Liu Y, Yang Z, Lin L, Yu G, Zhang F, Zhang G, Duan H.. Double-Layered Plasmonic–Magnetic Vesicles by Self-Assembly of Janus Amphiphilic Gold–Iron(II,III) Oxide Nanoparticles. Angew Chemie - Int Ed 2017;56:8110–4. doi:10.1002/anie.201702572.

[32] Castro N, Constantin D, Davidson P, Abécassis B. Solution self-assembly of plasmonic Janus nanoparticles. Soft Matter 2016;12:9666–73. doi:10.1039/C6SM01632D.

[33] Morton SW, Lee MJ, Deng ZJ, Dreaden EC, Siouve E, Shopsowitz KE, Shah NJ, Yaffe MB, Hammond PT. A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways. Sci Signal 2014;7:ra44. doi:10.1126/scisignal.2005261.

[34] Reddy TL, Rao K, Reddy SG, Reddy BVS, Yadav JS, Bhadra U, Bhadra MP. Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma. Sci Rep 2016:1–12. doi:10.1038/srep35223.

[35] Kuai R, Subramanian C, White PT, Timmermann BN, Moon JJ, Cohen MS, Schwendeman A. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. Int J Nanomedicine 2017;12:6581–94. doi:10.2147/IJN.S140591

[36] Guo Y, Yuan W, Yu B, Kuai R, Hu W, Morin EE, Garcia-Barrio MT, Zhang J, Moon JJ, Schwendeman A, Chen YE. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression. EBio Med 2018;28:225-33. doi:10.1016/j.ebiom.2017.12.021

[37] Yuet KP, Hwang DK, Haghogooie R, Doyle PS. Multifunctional Superparamagnetic Janus Particles.

Langmuir 2010;26:4281–7. doi:10.1021/la903348s.

[38] Roh K, Martin DC, Lahann J. Biphasic Janus particles with nanoscale anisotropy. Nat Mater 2005;4:759–63. doi:10.1038/nmat1486.

[39] Hwang S, Roh K-H, Lim DW, Wang G, Uher C, Lahann J. Anisotropic hybrid particles based on electrohydrodynamic co-jetting of nanoparticle suspensions. Phys Chem Chem Phys 2010;12:11894–9. doi:10.1039/c0cp00264j.

[40] Wang Y, Zhang Y, Wang B. Fabrication of core – shell micro/nanoparticles for programmable dual drug release by emulsion electrospraying. J Nanopart Res 2013;15:1-12. doi:10.1007/s11051-013-1726-y.

[41] Cao Y, Wang B, Wang Y, Lou D. Dual Drug Release from Core–Shell Nanoparticles with Distinct Release Profiles. J Pharm Sci 2014;103:3205–16. doi:10.1002/jps.24116.

[42] Duarte AR it. C, Ünal B, Mano JF, Reis RL, Jensen KF. Microfluidic production of perfluorocarbon-alginate core-shell microparticles for ultrasound therapeutic applications. Langmuir 2014;30:12391–9. doi:10.1021/la502822v.

[43] Cha C, Oh J, Kim K, Qiu Y, Joh M, Shin SR, Wang X, Camci-Unal G, Wan KT, Liao R, Khademhosseini A. Microfluidics-assisted fabrication of gelatin-silica core-shell microgels for injectable tissue constructs. Biomacromolecules 2014;15:283–90. doi:10.1021/bm401533y.

[44] Roh KH, Martin DC, Lahann J. Triphasic nanocolloids. J Am Chem Soc 2006;128:6796–7. doi:10.1021/ja060836n.

[45] Nahire R, Haldar MK, Paul S, Mergoum A, Ambre AH, Katti KS, Gange KN, Srivastava DK, Sarkar K, Mallik S. Polymer Coated Echogenic Lipid Nanoparticles with Dual Release Triggers. Biomacromolecules 2013;14:841–53. doi:10.1021/bm301894z.Polymer.

[46] Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 2013;7:9571–84. doi:10.1021/nn4047925.

[47] Liu Y, Huang B, Zhu J, Feng K, Yuan Y, Liu C. Dual-generation dendritic mesoporous silica nanoparticles for co-delivery and kinetically sequential drug release. RSC Adv 2018;8:40598–610. doi:10.1039/c8ra07849a.

[48] Devaraj NK, Keliher EJ, Thurber GM, Nahrendorf M. 18F Labeled Nanoparticles for in Vivo PET-CT Imaging. Bioconjug Chem 2009;20:397–401. doi:10.1021/bc8004649.18.

[49] Reynolds CH, Annan N, Beshah K, Huber JH, Shaber SH, Lenkinski RE, Wortman JA. Gadolinium-loaded nanoparticles: New contrast agents for magnetic resonance imaging. J Am Chem Soc 2000;122:8940–5. doi:10.1021/ja001426g.

[50] Liu Y, Chen Z, Liu C, Yu D, Lu Z, Zhang N. Gadolinium-loaded polymeric nanoparticles modified

with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials 2011;32:5167–76. doi:10.1016/j.biomaterials.2011.03.077.

[51] Strozyk MS, Aberasturi DJ De, Gregory J V, Brust M, Lahann J, Liz-Marzán LM. Spatial Analysis of Metal – PLGA Hybrid Microstructures Using 3D SERS Imaging 2017;1701626:1–7. doi:10.1002/adfm.201701626.

[52] Misra AC, Bhaskar S, Clay N, Lahann J. Multicompartmental Particles for Combined Imaging and siRNA Delivery. Adv Mater 2012;24:3850–6. doi:DOI 10.1002/adma.201200372.

[53] Hwang S, Lahann J. Differentially degradable janus particles for controlled release applications. Macromol Rapid Commun 2012;33:1178–83. doi:10.1002/marc.201200054.

[54] Rahmani S, Ross AM, Park TH, Durmaz H, Dishman AF, Prieskorn DM, Jones N, Altschuler RA, Lahann J. Dual Release Carriers for Cochlear Delivery. Adv Healthc Mater 2016;5:94–100. doi:10.1002/adhm.201500141.

[55] Gröschel AH, Walther A, Löbling TI, Schacher FH, Schmalz H, Müller AHE. Guided hierarchical co-assembly of soft patchy nanoparticles. Nature 2013;503:247–51. doi:10.1038/nature12610.

[56] Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012;9:1319–23. doi:10.1517/17425247.2012.720969.

[57] Zhang P, Sun F, Liu S, Jiang S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J Control Release 2016;284:183–93. doi:10.1016/j.jconrel.2016.06.040.

[58] Ayer M, Klok H. Cell-mediated delivery of synthetic nano- and microparticles. J Control Release 2017;259:92–104. doi:10.1016/j.jconrel.2017.01.048.

[59] Brenner JS, Pan DC, Myerson JW, Marcos-Contreras OA, Villa CH, Patel P, Hekierski H, Chatterjee S, Tao JQ, Parhiz H, Bhamidipati K. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nat Commun 2018;9:1-14. doi:10.1038/s41467-018-05079-7.

[60] Doshi N, Swiston AJ, Gilbert JB, Alcaraz ML, Cohen RE, Rubner MF, Mitragotri S. Cell-Based Drug Delivery Devices Using Phagocytosis- Resistant Backpacks. Adv Mater 2011;23:H105-9. doi:10.1002/adma.201004074.

[61] Mooney R, Weng Y, Garcia E, Bhojane S, Smith-Powell L, Kim SU, Annala AJ, Aboody KS, Berlin JM. Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy. J Control Release 2014;191:82-9. doi:10.1016/j.jconrel.2014.06.015.

[62] Muzykantov VR. Drug delivery by red blood cells : vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7:403-27. doi:10.1517/17425241003610633.

[63] Tomaiuolo G. Biomechanical properties of red blood cells in health and disease towards

microfluidics. Biomicrofluidics 2014;8:051501. doi:10.1063/1.4895755.

[64] Pang L, Zhang C, Qin J, Han L, Li R, Hong C, He H, Wang J. A novel strategy to achieve effective drug delivery : exploit cells as carrier combined with nanoparticles. Drug Deliv 2017 ;24:83-91. doi:10.1080/10717544.2016.1230903.

[65] Wu Z, Li T, Li J, Gao W, Xu T, Christianson C, Gao W, Galarnyk M, He Q, Zhang L, Wang J. Turning Erythrocytes into Functional Micromotors. ACS Nano 2014;8:12041-8. doi:10.1021/nn506200x.

[66] Villa CH, Seghatchian J, Muzykantov V. Transfusion and Apheresis Science Drug Delivery by Erythrocytes : " Primum non nocere ". Transfus Apher Sci 2016;55:275–80. doi:10.1016/j.transci.2016.10.017.

[67] Villa CH, Cines DB, Siegel DL, Muzykantov V. Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond. Transfus Med Rev 2017. doi:10.1016/j.tmrv.2016.08.004.

[68] Chambers E, Mitragotri S. Long Circulating Nanoparticles via Adhesion on Red Blood Cells : Mechanism and Extended Circulation. Exp Biol Med 2007;232:958–66.

[69] Villa CH, Anselmo AC, Mitragotri S, Muzykantov V. Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv Drug Deliv Rev 2016;106:88-103. doi:10.1016/j.addr.2016.02.007.

[70] Chambers E, Mitragotri S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J Control Release 2004;100:111-9. doi:10.1016/j.jconrel.2004.08.005.

[71] Anselmo AC, Gupta V, Zern BJ, Pan D, Zakrewsky M, Muzykantov V, Mitragotri S. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 2013;7:11129-37. doi:10.1021/nn404853z.

[72] Anselmo AC, Kumar S, Gupta V, Pearce AM, Ragusa A, Muzykantov V, Mitragotri S. Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: Synergy between physical, chemical and biological approaches. Biomaterials 2015;68:1-8. doi:10.1016/j.biomaterials.2015.07.043.

[73] Wiley DT, Webster P, Gale A, Davis ME. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci 2013;110:8662–7. doi:10.1073/pnas.1307152110.

[74] Pan DC, Myerson JW, Brenner JS, Patel PN, Anselmo AC, Mitragotri S, Muzykantov V. Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells. Sci Rep 2018;8:1-12. doi:10.1038/s41598-018-19897-8.

[75] Pan D, Vargas-Morales O, Zern B, Anselmo AC, Gupta V, Zakrewsky M, Mitragotri S, Muzykantov V. The effect of polymeric nanoparticles on biocompatibility of carrier red blood cells. PLoS One

2016;11:1-17. doi:10.1371/journal.pone.0152074.

[76] Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell 2010; 140:883-99. doi:10.1016/j.cell.2010.01.025.

[77] Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery systems. Pharm Res 2014; 31:2563-82. doi:10.1007/s11095-014-1419-y.

[78] Nourshargh S, Alon R. Leukocyte Migration into Inflamed Tissues. Immunity 2014; 41:694-707. doi:10.1016/j.immuni.2014.10.008.

[79] Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953–64. doi:10.1038/nri1733.

[80] Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224–34. doi:10.1182/blood-2004-03-1109.

[81] Lewis C, Murdoch C. Macrophage Responses to Hypoxia. Am J Pathol 2005;167:627–35. doi:10.1016/S0002-9440(10)62038-X.

[82] H Evans MA, Huang PJ, Iwamoto Y, Ibsen KN, Chan EM, Hitomi Y, Ford PC, Mitragotri S. Macrophage-mediated delivery of light activated nitric oxide prodrugs with spatial, temporal and concentration control. Chem Sci 2018;9:3729–41. doi:10.1039/c8sc00015h.

[83] Moore TL, Hauser D, Gruber T, Rothen-Rutishauser B, Lattuada M, Petri-Fink A, Lyck R. Cellular Shuttles: Monocytes/Macrophages Exhibit Transendothelial Transport of Nanoparticles under Physiological Flow. ACS Appl Mater Interfaces 2017. doi:10.1021/acsami.7b03479.

[84] Si J, Shao S, Shen Y, Wang K. Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy. Small 2016:5108–19. doi:10.1002/smll.201601282.

[85] Batrakova E V, Li S, Reynolds AD, Mosley RL, Bronich TK, Kabanov A V, Gendelman HE. A Macrophage - Nanozyme Delivery System for Parkinson's Disease 2007:1498–506. doi:10.1021/bc700184b.

[86] Amani SB, Makkouk R, Sun TKC. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol 2011;104:439–48. doi:10.1007/s11060-010-0511-3.

[87] Madsen SJ, Christie C, Hong SJ, Trinidad A, Peng Q, Uzal FA, Hirschberg H. Nanoparticle-loaded macrophage-mediated photothermal therapy: potential for glioma treatment. Lasers Med Sci 2015;30:1357-65. doi:10.1007/s10103-015-1742-5.

[88] Choi J, Kim H, Jin E, Jung J, Park J, Chung HK, Lee JS, Lee JS, Park HJ, Song SY, Jeong SY. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 2012;33:4195–203. doi:10.1016/j.biomaterials.2012.02.022.

[89] Batrakova E V, Gendelman HE, Kabanov A V, Batrakova E V, Gendelman HE, Kabanov A V. Cell-mediated drug delivery. Expert Opin Drug Deliv 2011;8:415-433. doi:10.1517/17425247.2011.559457.

[90] Klyachko NL, Polak R, Haney MJ, Zhao Y, Gomes Neto RJ, Hill MC, Kabanov AV, Cohen RE, Rubner MF, Batrakova EV. Macrophages with cellular backpacks for targeted drug delivery to the brain. Biomaterials 2017;140:79-87. doi:10.1016/j.biomaterials.2017.06.017.

[91] Jiang P, Yu C, Yen C, Woo CW. Irradiation Enhances the Ability of Monocytes as Nanoparticle Carrier for Cancer Therapy. PloS one 2015;10:1–15. doi:10.1371/journal.pone.0139043.

[92] Swiston AJ, Cheng C, Um SH, Irvine DJ, Cohen RE, Rubner MF. Surface functionalization of living cells with multilayer patches. Nano Lett 2008; 8:4446-53. doi:10.1021/nl802404h.

[93] Swiston AJ, Gilbert JB, Irvine DJ, Cohen RE, Rubner MF. Freely Suspended Cellular "Backpacks" Lead to Cell Aggregate Self-Assembly. Biomacromolecules 2010;11:1826-32. doi: 10.1021/bm100305h.

[94] Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interf Cytok Res 2009;29:313-26. doi:10.1089/jir.2008.0027.

[95] Anselmo AC, Gilbert JB, Kumar S, Gupta V, Cohen RE, Rubner MF, Mitragotri S. Monocyte-mediated delivery of polymeric backpacks to in fl amed tissues : a generalized strategy to deliver drugs to treat inflammation. J Control Release 2015;199:29–36. doi:10.1016/j.jconrel.2014.11.027.

[96] Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 2012;12:269-81. doi:10.1038/nri3191.

[97] Stephan MT, Moon JJ, Um SH, Bersthteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010;16:1035-41. doi:10.1038/nm.2198.

[98] Huang B, Abraham WD, Zheng Y, Bustamante López SC, Luo SS, Irvine DJ. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci Transl Med 2015;7: 291ra94. doi: 10.1126/scitranslmed.aaa5447.

[99] Wayteck L, Dewitte H, De Backer L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes. Biomaterials 2016;77:243-54. doi:10.1016/j.biomaterials.2015.11.016.

[100] Fliervoet LAL, Mastrobattista E. Drug delivery with living cells. Adv Drug Deliv Rev 2016;106:63-72. doi:10.1016/j.addr.2016.04.021.

[101] Tan S, Wu T, Zhang D, Zhang Z. Theranostics Cell or Cell Membrane-Based Drug Delivery Systems 2015;5:16–21. doi:10.7150/thno.11852.

[102] Mimeault M, Hauke R, Batra SK. Stem cells: A revolution in therapeutics - Recent advances in

stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther 2007;82:252-64. doi:10.1038/sj.clpt.6100301.

[103] Corsten MF, Shah K. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol 2008; 9:376–84. doi: 10.1016/S1470-2045(08)70099-8.

[104] Huang X, Zhang F, Wang H, Niu G, Choi KY, Swierczewska M, Zhang G, Gao H, Wang Z, Zhu L, Choi HS. Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery. Biomaterials 2013;34:1772-8. doi:10.1016/j.biomaterials.2012.11.032.

[105] Therapy T, Li L, Guan Y, Liu H, Hao N, Liu T, Meng X, Fu C, Li Y, Qu Q, Zhang Y, Ji S. Silica Nanorattle-Doxorubicin-Anchored Mesenchymal Stem Cells for Tumor-Tropic Therapy. ACS Nano 2011;5:7462–70. doi:10.1021/nn202399w.

[106] Roger M, Clavreul A, Venier-Julienne MC, Passirani C, Sindji L, Schiller P, Montero-Menei C, Menei P. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010; 31:8393-401. doi:10.1016/j.biomaterials.2010.07.048.

[107] Mooney R, Roma L, Zhao D, Van Haute D, Garcia E, Kim SU, Annala AJ, Aboody KS, Berlin JM. Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy. ACS Nano 2014; 8:12450-60. doi:10.1021/nn505147w.

[108] Ding S, O'Banion CP, Welfare JG, Lawrence DS. Cellular Cyborgs: On the Precipice of a Drug Delivery Revolution. Cell Chem Biol 2018;25:648-58. doi:10.1016/j.chembiol.2018.03.003.

[109] Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles : Taking advantage of circulatory cells to target nanoparticles. J Control Release 2014;190:531–41. doi:10.1016/j.jconrel.2014.03.050.

[110] Singh B, Mitragotri S. Harnessing cells to deliver nanoparticle drugs to treat cancer. Biotechnol Adv 2019:0–1. doi:10.1016/j.biotechadv.2019.01.006.

[111] Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235:179–92. doi:10.1016/S0378-5173(01)00986-3.

[112] Desai N. Nab Technology: A Drug Delivery Platform Utilising Endothelial gp60 Receptor-based Transport and Tumour-derived SPARC for Targeting. Drug Deliv Rep 2007;16:37-41.

[113] Thao LQ, Lee C, Kim B, Lee S, Kim TH, Kim JO, Lee ES, Oh KT, Choi HG, Yoo SD, Youn YS. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma. Colloids Surfaces B Biointerfaces 2017;152:183–91. doi:10.1016/j.colsurfb.2017.01.017.

[114] Kinoshita R, Ishima Y, Chuang VT, Nakamura H, Fang J, Watanabe H, Shimizu T, Okuhira K, Ishida T, Maeda H, Otagiri M, Maruyama T. Improved anticancer effects of albumin-bound paclitaxel

nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer. Biomaterials 2017;140:162–9. doi:10.1016/j.biomaterials.2017.06.021.

[115] Sparreboom A, Scripture CD, Trieu V, Williams P, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136–43. doi:10.1158/1078-0432.CCR-04-2291.

[116] Ruttala HB, Ko YT. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy. Pharm Res 2015;32:1002–16. doi:10.1007/s11095-014-1512-2.

[117] Ruttala HB, Ramasamy T, Shin BS, Choi HG, Yong CS, Kim JO. Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel. Int J Pharm 2017;519:11–21. doi:10.1016/j.ijpharm.2017.01.011.

[118] Tian L, Chen Q, Yi X, Wang G, Chen J, Ning P, Yang K, Liu Z. Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer. Theranostics 2017;7:614–23. doi:10.7150/thno.17381.

[119] Ruttala HB, Ko YT. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy. Colloids Surfaces B Biointerfaces 2015;128:419–26. doi:10.1016/J.COLSURFB.2015.02.040.

[120] Neil P. Desai. Nanoparticle Compositions of Albumin and Paclitaxel, 2014. United States patent application US 13/794,705.

[121] Estrada LH, Chu S, Champion JA. Protein nanoparticles for intracellular delivery of therapeutic enzymes. J Pharm Sci 2014;103:1863–71. doi:10.1002/jps.23974.

[122] Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876–85. doi:10.1016/j.addr.2007.08.044.

[123] Tan YL, Ho HK. Navigating albumin-based nanoparticles through various drug delivery routes. Drug Discov Today 2018;23:1108–14. doi:10.1016/j.drudis.2018.01.051.

[124] Yeates TO, Liu Y, Laniado J. The design of symmetric protein nanomaterials comes of age in theory and practice. Curr Opin Struct Biol 2016;39:134–43. doi:10.1016/j.sbi.2016.07.003.

[125] Arai R. Hierarchical design of artificial proteins and complexes toward synthetic structural biology. Biophys Rev 2018;10:391–410. doi:10.1007/s12551-017-0376-1.

[126] Molino NM, Wang SW. Caged protein nanoparticles for drug delivery. Curr Opin Biotechnol 2014;28:75–82. doi:10.1016/j.copbio.2013.12.007.

[127] Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci 2011;108:16998–7003.

doi:10.2139/ssrn.2955110.

[128] Zhen Z, Tang W, Chen H, Lin X, Todd T, Wang G, Cowger T, Chen X, Xie J. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 2013;7:4830–7. doi:10.1021/nn305791q.

[129] Kawakami N, Kondo H, Matsuzawa Y, Hayasaka K, Nasu E, Sasahara K, Arai R, Miyamoto K. Design of Hollow Protein Nanoparticles with Modifiable Interior and Exterior Surfaces. Angew Chemie - Int Ed 2018;57:12400–4. doi:10.1002/anie.201805565.

[130] Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs 2015;7:9–14. doi:10.4161/19420862.2015.989042.

[131] Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 2000;194:91–102. doi:10.1016/S0378-5173(99)00370-1.

[132] Von Storp B, Engel A, Boeker A, Ploeger M, Langer K. Albumin nanoparticles with predictable size by desolvation procedure. J Microencapsul 2012;29:138–46. doi:10.3109/02652048.2011.635218.

[133] Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N, Faust S, Vogel V. Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 2008;347:109–17. doi:10.1016/j.ijpharm.2007.06.028.

[134] Dreis S, Rothweiler F, Michaelis M, Cinatl J, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 2007;341:207–14. doi:10.1016/j.ijpharm.2007.03.036.

[135] Herrera Estrada LP, Champion JA. Protein nanoparticles for therapeutic protein delivery. Biomater Sci 2015;3:787–99. doi:10.1039/C5BM00052A.

[136] Fathi M, Donsi F, McClements DJ. Protein-Based Delivery Systems for the Nanoencapsulation of Food Ingredients. Compr Rev Food Sci Food Saf 2018;17:920–36. doi:10.1111/1541-4337.12360.

[137] Shao S, Shen X, Guo M. Zinc-loaded whey protein nanoparticles prepared by enzymatic cross-linking and desolvation. Int J Food Sci Technol 2018;53:2205–11. doi:10.1111/ijfs.13809.

[138] Chang TZ, Stadmiller SS, Staskevicius E, Champion JA. Effects of ovalbumin protein nanoparticle vaccine size and coating on dendritic cell processing. Biomater Sci 2017;5:223–33. doi:10.1039/c6bm00500d.

[139] Tsoras AN, Champion JA. Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine. Bioconjug Chem 2018;29:776–85. doi:10.1021/acs.bioconjchem.8b00079.

[140] Deng L, Mohan T, Chang TZ, Gonzalez GX, Wang Y, Kwon YM, Kang SM. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat Commun 2018;9:359. doi:10.1038/s41467-017-02725-4.

[141] Fiers W, De Filette M, Bakkouri K El, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. M2e-based universal influenza A vaccine. Vaccine 2009;27:6280–3. doi:10.1016/J.VACCINE.2009.07.007.

[142] Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011;29:5145–52. doi:10.1016/J.VACCINE.2011.05.041.

[143] Chang TZ, Deng L, Wang B-Z, Champion JA. H7 Hemagglutinin nanoparticles retain immunogenicity after >3 months of 25 degrees C storage. PLoS One 2018;13:e0202300. doi:10.1371/journal.pone.0202300.

[144] Dommelen SM Van, Vader P, Lakhal S, Kooijmans SAA, Solinge WW Van, Wood MJA, Schiffelers RM. . Microvesicles and exosomes : Opportunities for cell-derived membrane vesicles in drug delivery. J Control Release 2012;161:635–44. doi:10.1016/j.jconrel.2011.11.021.

[145] Batrakova E V, Kim MS. Using exosomes , naturally-equipped nanocarriers , for drug delivery. J Control Release 2015;219:396–405. doi:10.1016/j.jconrel.2015.07.030.

[146] Armstrong JPK, Stevens MM. Strategic design of extracellular vesicle drug delivery systems. Adv Drug Deliv Rev 2018;130:12–6. doi:10.1016/j.addr.2018.06.017.

[147] Alvarez-erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. letters Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011;29. doi:10.1038/nbt.1807.

[148] Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G. Biomaterials A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014;35:2383–90. doi:10.1016/j.biomaterials.2013.11.083.

[149] Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG. A Novel Nanoparticle Drug Delivery System : The Anti-inflammatory Activity of Curcumin Is Enhanced When Encapsulated in Exosomes. Mol Ther 2010;18:1606–14. doi:10.1038/mt.2010.105.

[150] Ingato D, Uk J, Jun S, Jik Y. Good things come in small packages : Overcoming challenges to harness extracellular vesicles for therapeutic delivery. J Control Release 2016;241:174–85. doi:10.1016/j.jconrel.2016.09.016.

[151] Arnold FH. Directed Evolution: Bringing New Chemistry to Life. Angew Chemie Int Ed 2018;57:4143–8. doi:10.1002/anie.201708408.



WNAN_1625_Abstract Figure.tif



WNAN_1625_Figure1.tif



WNAN_1625_Figure2.tif



WNAN_1625_Figure3.tif



WNAN_1625_Figure 4.tif